Candida and cryptococcal infections;Infecciones por Candida y criptococo

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 16, Issue SUPPL. 1, 1998, Pages 29-35

  Berenguer, Juan ^a   Blázquez, Rosa ^b   Ocaña, Inmaculada ^c   Lozano, Fernando ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CARBAMAZEPINE; CISAPRIDE; CLOTRIMAZOLE; CYCLOSPORIN; DIDANOSINE; DIGOXIN; FLUCONAZOLE; FLUCYTOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NYSTATIN; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; THEOPHYLLINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; MENINGITIS; NEUROLOGIC DISEASE; RELAPSE; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, ORAL; COMBINED MODALITY THERAPY; CRYPTOCOCCOSIS; DRAINAGE; HUMANS; MENINGITIS, CRYPTOCOCCAL; TREATMENT FAILURE;

EID: 0031740712     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Feigal DW, Katz MH, Greenspan D et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991; 5: 519-525.
2. White MH. Is vulvovaginal candidiasis an AIDS-related illness? Clin Infect Dis 1996; 22 (Supl 2): 124-127.
3. CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR 1997; 46 (RR-12): 1-46.
4. Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151: 1.567-1.572.
5. Laine L. The natural history of esophageal candidiasis after successful treatment in patients with AIDS. Gastroenterology 1994; 107: 744-746.
6. Rabeneck L, Laine L. Esophageal candidiasis in patients infected with the human immunodeficiency virus. A decision analysis to assess cost-effectiveness of alternative management strategies. Arch Intern Med 1994; 154: 2.705-2.710.
7. Wilcox CM, Straub RF, Alexander LN, Clark WS. Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Am J Med 1996; 101: 599-604.
8. Odds FC, Bernaerts R. CHROMagar Candida a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994; 32: 1.923-1.929.
9. Dronda F, Alonso-Sanz M, Laguna F et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996; 15: 446-452.
10. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141: 1.507-1.521.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Accepted standard M27-A. Villanova, Pa.: National Committee for Clinical Laboratory Standards 1997.
12. Laguna F, Rodríguez-Tudela JL, Martínez-Suárez JV et al. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997; 24: 124-130.
13. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole itraconazole and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-247.
14. Pons V, Greenspan D, Lozada-Nur F et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24: 1.204-1.207.
15. Murray PA, Koletar SL, Mallegol I, Wu J, Moskovitz BL. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther 1997; 19: 471-480.
16. De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989; 1: 746-748.
17. Laine L, Dretler RH, Conteas CN et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117: 655-660.
18. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG. Itraconazole versus ketaconazole in the treatment of oral and esophageal candidosis in patients infected with HIV. AIDS 1991; 5: 1.367-1.371.
19. Reynes J, Bazin C, Ajana F et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2.554-2.558.
20. Graybill JR, Vázquez J, Darouiche RO et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33-39.
21. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr 1993; 6: 1.311-1.316.
22. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized controlled clinical study. Scand J Infect Dis 1995; 27: 613-617.
23. Gil A, Lavilla P, López Dupla M et al. Tratamiento de la candidiasis esofágica con fluconazol en el síndrome de inmunodeficiencia adquirida. Estudio comparativo de dos pautas terapéuticas. Med Clin (Barc) 1992; 98: 612-617.
24. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990; 12 (Supl 3): 334-337.
25. Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700-705.
26. Schuman P, Capps L, Peng G et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126: 689-696.
27. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized double-blind placebo-controlled study of 100 mg oral fluconazole daily. Arch Intern Med 1991; 151: 2.458-2.464.
28. Marriott DJ, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 1993; 158: 312-316.
29. Dromer F, Improvisi L, Dupont B et al. Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS 1997; 11: 1.095-1.101.
30. White TC. Antifungal drug resistance in Candida albicans. ASM News 1997; 63: 427-433.
31. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 334: 1.674-1.675.
32. Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS 1998; 12: 538.
33. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21: 28-34.
34. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-548.
35. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72: 207-224.
36. Berenguer J. Diagnóstico de laboratorio de la criptococosis. Rev Iberoam Micol 1996; 12 (Supl): 82-83.
37. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994; 18: 789-792.
38. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301; 126-131.
39. Larsen RA, Bozzette S, McCutchan JA, Chiu J, Leal MA, Richman DD. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989; 111: 125-128.
40. Kovacs JA, Kovacs AA, Polis M et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 533-538.
41. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 794-799.
42. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Groupl N Engl J Med 1992; 326: 83-89.
43. Van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
44. Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992; 36: 690-692.
45. Milefchik E, Leal M, Haubrich R, See D, Bozzette S, Larsen R. High dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis [resumen n.o WS-B12-5]. Int Conf AIDS 1993; 9: 55.
46. Larsen RA Bozzette SA, Jones BE et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741-745.
47. Nguyen MH, Najvar LK, Yu CY, Graybill JR. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997; 41: 1.120-1.123.
48. Coker R, Tomlinson D, Harris J. Successful treatment of cryptococcal meningitis with liposomal amphotericin B after failure of treatment with fluconazole and conventional amphotericin B. AIDS 1990; 5: 231-232.
49. Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1.463-1.471.
50. Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-321.
51. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993; 37: 1.383-1.386.
52. Brandt ME, Pfaller MA, Hajjeh RA et al. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. Cryptococcal Disease Active Surveillance Group. J Infect Dis 1996; 174: 812-820.
53. Fessler RD, Sobel J, Guyot L et al. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J Acquir Immun Defic Syndr Hum Retrovirol 1998; 17: 137-142.
54. Witt MD, Lewis RJ, Larsen RA et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322-328.
55. Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC, Edwards JJ, Criddle RS. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992; 30: 2.881-2.886.
56. Sanati H, Messer SA, Pfaller M et al. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol 1996; 34: 1.280-1.282.